Header Logo

Connection

Raid Aljumaily to Survival Rate

Back to Details
This is a "connection" page, showing publications Raid Aljumaily has written about Survival Rate.
Raid Aljumaily
Connection Strength
0.039
Survival Rate
  1. Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial. Ann Oncol. 2019 10 01; 30(10):1613-1621.
    View in: PubMed
    Score: 0.039
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.